ActoFactor™ Recombinant Human Nicotinamide phosphoribosyltransferase

CSC-CTK0622

Excess adiposity is the most important risk in the development of insulin resistance and type 2 diabetes mellitus (T2DM). Adipose tissue produces several proteins (adipocytokines) such as leptin, adiponectin, resistin, tumor necrosis factor-α, and IL-6, that modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms by which fat tissue induces insulin resistance and the role of adipocytokines in the pathogenesis of T2DM have not been fully investigated. Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is a cytokine that is highly expressed in visceral fat and was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B-cell precursors. Visfatin homologs have been identified in carp, invertebrate mollusks, and bacteria, as well as in vertebrates, including humans and the mouse. It has been postulated to play a role in innate immunity.Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulin-deficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes. Human recombinant Visfatin produced in E. coli is a single, non-glycosylated polypeptide chain of 348 amino acids having an 11 N-terminal Flag-tag and a total molecular mass is 39.6 kDa (calculated). The amino acid sequence of the recombinant human Visfatin is 100% homologous to the amino acid sequence Pro27-Glu363 of human Visfatin. The Visfatin has been purified by using Flag-affinity chromatography.

Human

Human NAMPT expressed in E.coli

40 kDa

CAT# CSC-CTK0622-25 (25 μg); CAT# CSC-CTK0622-125 (125 μg)

E.coli

Greater than 95% as determined by SDS-PAGE analysis.

N/A

N/A

Filtered (0.4 μm) and lyophilized from a protein solution (0.5 mg/ml) in 20 mM Tris, 20 mM NaCl (pH 7.5).

Please centrifuge product briefly before opening the vial. Add 20 mM Tris, 20 mM NaCl (pH 7.5) to prepare a working stock solution of approximately 0.5 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.

The lyophilized powder, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted protein should be stored long-term in undiluted working aliquots at –20°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze / thaw cycles. Applications ELISA, Western Blot

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.